Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Vtama Zoryve Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Topical Products – Vtama and Zoryve Step Therapy Policy

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Vtama (tapinarof 1% cream) and Zoryve (roflumilast 0.3% cream) for plaque psoriasis, requiring specified topical therapy trials subject to age and site-specific criteria.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyTopical Products – Vtama and Zoryve Step Therapy Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2023
    Last ReviewNov 16, 2022
    Next Review DateN/A
    Key ActionSubmit the requested product, patient age, plaque psoriasis treatment site, and history of qualifying Step 1 product trials.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Step 2 products covered by this policy
    130 daysAutomated Step 1 history lookback period
    1 yearDuration of approved coverage
    ≥18 yearsMinimum age for Vtama
    ≥12 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Minimum age for Zoryve

    Coverage Criteria

    Vtama initial coverage

    Approve Vtama when all of the following are met:

    Vtama approval

    • Age requirement

      • Patient is 18 years of age or older.≥18 years
    • Qualifying therapy pathway

      • Step 1a plus Step 1b

        • Patient has tried one Step 1a Product.
        • Patient has tried one Step 1b Product.
      • Step 1c

        • Patient has tried one Step 1c Product.
      • Special-site pathway

        • Patient is treating plaque psoriasis affecting one of the following areas: face, eyes/eyelids, skin folds, and/or genitalia.
        • Patient has tried one Step 1b Product.

    Zoryve initial coverage

    Approve Zoryve when all of the following are met:

    Zoryve approval

    • Age requirement

      • Patient is 12 years of age or older.≥12 years
    • Qualifying therapy pathway

      • Step 1a plus Step 1b

        • Patient has tried one Step 1a Product.
        • Patient has tried one Step 1b Product.
      • Step 1c

    Age-based exclusions apply: patients younger than 12 years are excluded from Zoryve coverage, and patients younger than 18 years are excluded from Vtama coverage.

    Prior Authorization and Provider Actions

    Prior Authorization

    Prior Authorization Required

    Submit prior authorization for the requested Step 2 product, documenting the patient’s age, treatment site, and qualifying Step 1 history. Approved authorizations are valid for 1 year.

    • Requested products: Vtama or Zoryve
    • Document patient age and treatment site, including whether plaque psoriasis affects the face, eyes/eyelids, skin folds, and/or genitalia
    • Document qualifying Step 1 product history; a history within the 130-day lookback period excludes the patient from Step Therapy
    Step Therapy

    Required Step 1 Therapy

    Before coverage of Vtama or Zoryve, verify that the patient has completed the required Step 1 therapy. The requirement is met by either one Step 1a product plus one Step 1b product, or one Step 1c combination product.

    • Step 1a: a medium-, medium-high, high-, or super-high-potency prescription topical corticosteroid; brand and generic products qualify

    Clinical Background

    Plaque psoriasis is commonly managed initially with topical therapy, including topical corticosteroids, vitamin D analogs, and combination products. Under this policy, Step 1 therapies are used before the Step 2 products, Vtama and Zoryve. Standard treatment requires a trial of one Step 1a topical corticosteroid and one Step 1b topical vitamin D analog, or one Step 1c corticosteroid/vitamin D analog combination product. For plaque psoriasis affecting the face, eyes or eyelids, skin folds, and/or genitalia, one Step 1b product is required.

    Therapy Definitions

    Step 1a Product
    Product typePrescription topical corticosteroid
    Qualifying potency categoriesMedium, medium-high, high, or super-high potency
    Product statusBrand and generic products qualify
    Product listProducts listed in Table 1 of the policy
    Step 1b Product
    Product typeTopical vitamin D analog
    Calcipotriene0.005% cream, foam, ointment, or solution

    Initial Therapy by Product

    Vtama minimum age and qualifying pathway

    Vtama is covered when the patient meets the age requirement and one qualifying therapy pathway:

    Vtama eligibility

    • Minimum age

      • Patient is 18 years of age or older.≥18 years
    • Qualifying Step 1 or special-site pathway

      • Step 1a plus Step 1b

        • Patient has tried one Step 1a Product.

    Step Therapy Product Lists and Bypass Rules

    Potency categoryTopical corticosteroidStrengthFormulation(s)Brand or generic status
    Super-high potencyBetamethasone dipropionate, augmented0.05%Ointment; gelBrand and generic prescription products
    Super-high potencyClobetasol propionate0.05%Cream; foam; gel; lotion; ointment; shampooBrand and generic prescription products
    Super-high potencyDiflorasone diacetate0.05%OintmentBrand and generic prescription products
    Super-high potencyFluocinonide0.1%CreamBrand and generic prescription products
    Super-high potencyFlurandrenolide4 mcg/m²TapeBrand and generic prescription products
    Super-high potencyHalobetasol propionate0.05%Cream; ointment; lotionBrand and generic prescription products
    High potencyAmcinonide0.1%OintmentBrand and generic prescription products
    High potencyBetamethasone dipropionate, augmented0.05%Cream; lotionBrand and generic prescription products
    High potencyBetamethasone dipropionate0.05%Cream; ointmentBrand and generic prescription products
    High potencyDesoximetasone0.25%Cream; ointment; sprayBrand and generic prescription products
    High potencyFluocinonide0.05%Cream; gel; ointment; solutionBrand and generic prescription products
    High potencyHalcinonide0.1%CreamBrand and generic prescription products
    High potencyMometasone furoate0.1%OintmentBrand and generic prescription products
    High potencyTriamcinolone acetonide0.5%OintmentBrand and generic prescription products
    Medium-high potencyAmcinonide0.1%Cream; lotionBrand and generic prescription products
    Medium-high potencyBetamethasone valerate0.1%OintmentBrand and generic prescription products
    Medium-high potencyDiflorasone diacetate0.05%CreamBrand and generic prescription products
    Medium-high potencyFluocinonide-E0.05%CreamBrand and generic prescription products
    Medium-high potencyFluticasone propionate0.005%OintmentBrand and generic prescription products
    Medium-high potencyHalcinonide0.1%OintmentBrand and generic prescription products
    Medium-high potencyTriamcinolone acetonide0.5%CreamBrand and generic prescription products
    Medium-high potencyTriamcinolone acetonide0.1%OintmentBrand and generic prescription products
    Medium potencyBetamethasone valerate0.12%FoamBrand and generic prescription products
    Medium potencyDesoximetasone0.05%CreamBrand and generic prescription products
    Medium potencyFluocinolone acetonide0.025%OintmentBrand and generic prescription products
    Medium potencyFlurandrenolide0.05%OintmentBrand and generic prescription products
    Medium potencyHydrocortisone valerate0.2%OintmentBrand and generic prescription products
    Medium potencyMometasone furoate0.1%Cream; lotion; solutionBrand and generic prescription products
    Medium potencyPrednicarbate0.1%OintmentBrand and generic prescription products
    ProductStrengthFormulationListed product or brand
    Calcipotriene0.005%CreamDovonex; generic
    Calcipotriene0.005%Foam
    Calcipotriene0.005%Ointment
    Calcipotriene0.005%Solution
    Calcitriol3 mcg/gOintmentVectical; generic
    SoriluxSorilux
    Qualifying combination productStrengthFormulationListed brands
    Calcipotriene plus betamethasone dipropionateCalcipotriene 0.005% plus betamethasone dipropionate 0.064%Ointment or suspensionTaclonex, generic; Enstilar; Wynzora
    Qualifying claims historyLookback periodStep Therapy result
    One Step 1a product and one Step 1b productPreceding 130 daysStep Therapy bypassed
    One Step 1c productPreceding 130 daysStep Therapy bypassed
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyTopical Products – Vtama and Zoryve Step Therapy Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2023
    Last ReviewNov 16, 2022
    Next Review DateN/A
    Key ActionSubmit the requested product, patient age, plaque psoriasis treatment site, and history of qualifying Step 1 product trials.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and Provider ActionsClinical BackgroundTherapy DefinitionsInitial Therapy by ProductStep Therapy Product Lists and Bypass Rules
  1. Patient has tried one Step 1c Product.
  2. Special-site pathway

    • Patient is treating plaque psoriasis affecting one of the following areas: face, eyes/eyelids, skin folds, and/or genitalia.
    • Patient has tried one Step 1b Product.
  3. Step 1b: calcipotriene, calcitriol, or Sorilux formulations
  4. Step 1c alternative: calcipotriene/betamethasone products, Enstilar, or Wynzora
  5. A patient with one Step 1a and one Step 1b product, or one Step 1c product, within the 130-day lookback period is excluded from Step Therapy
  6. Denial Risk

    Age Edit

    Apply the product-specific minimum age edit before approving coverage. Deny coverage when the patient is below the applicable minimum age.

    • Vtama: patient must be ≥ 18 years; deny if < 18 years
    • Zoryve: patient must be ≥ 12 years; deny if < 12 years
    Denial Risk

    Unmet Step Therapy Criteria

    Deny coverage when the applicable age requirement or Step 1 criteria are not met. For plaque psoriasis affecting the face, eyes/eyelids, skin folds, or genitalia, the alternative pathway requires a trial of one Step 1b product; no other exceptions are recommended.

    • Vtama: patient must be ≥ 18 years and must have tried one Step 1a plus one Step 1b product, or one Step 1c product, or one Step 1b product when treating an identified sensitive site
    • Zoryve: patient must be ≥ 12 years and must have tried one Step 1a plus one Step 1b product, or one Step 1c product, or one Step 1b product when treating an identified sensitive site
    • If the required age or qualifying Step 1 history is not documented or is not met, do not approve coverage
    Calcitriol3 mcg/g ointment
    Additional productSorilux
    Step 1c Product
    Product typeTopical combination product containing calcipotriene and betamethasone dipropionate
    Active ingredients and strengthsCalcipotriene 0.005% plus betamethasone dipropionate 0.064%
    Qualifying formulationsOintment or suspension
    Named productsTaclonex, Enstilar, and Wynzora
    Step 2 Product
    Step 2 productsVtama and Zoryve
    VtamaVtama
    ZoryveZoryve
    Patient has tried one Step 1b Product.
  7. Step 1c

    • Patient has tried one Step 1c Product.
  8. Special-site pathway

    • Patient is treating plaque psoriasis affecting one of the following areas: face, eyes/eyelids, skin folds, and/or genitalia.
    • Patient has tried one Step 1b Product.
  9. Zoryve minimum age and qualifying pathway

    Zoryve is covered when the patient meets the age requirement and one qualifying therapy pathway:

    Zoryve eligibility

    • Minimum age

      • Patient is 12 years of age or older.≥12 years
    • Qualifying Step 1 or special-site pathway

      • Step 1a plus Step 1b

        • Patient has tried one Step 1a Product.
        • Patient has tried one Step 1b Product.
      • Step 1c

        • Patient has tried one Step 1c Product.
      • Special-site pathway

        • Patient is treating plaque psoriasis affecting one of the following areas: face, eyes/eyelids, skin folds, and/or genitalia.
        • Patient has tried one Step 1b Product.